Systemic Lupus Erythematosus Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Systemic Lupus Erythematosus Pipeline Insight 2024" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in the Systemic Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including Systemic Lupus Erythematosus clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Systemic Lupus Erythematosus Research. Learn more about our innovative pipeline today! @ Systemic Lupus Erythematosus Pipeline Outlook- https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Systemic Lupus Erythematosus Pipeline Report
• In November 2024:- Bristol-Myers Squibb- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2). The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
• In November 2024:- Gracell Biotechnologies (Shanghai) Co., Ltd.- This is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory SLE；The dose-escalation phase 1 study aims to assess the safety of GC012F Injection and determine the Recommended Phase II Dose (RP2D). The phase 2 study aims to determine the efficacy and safety of GC012F Injection at the RP2D in patients with refractory SLE and assess the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics.
• In November 2024:- Zenas BioPharma (USA), LLC- This study consists of a 24-week treatment period followed by a 12-week follow-up period. Patients must have a clinical diagnosis of SLE at least 24 weeks prior to screening and meet the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria. To enter the Screening Period (Day -28 to Day -1) patients will have active SLE as defined by having: a) hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) ≥ 6 and clinical hSLEDAI ≥ 4, and b) British Isles Lupus Assessment Group (BILAG)-2004 Grade A or B in ≥ 1 organ system.
• DelveInsight's Systemic Lupus Erythematosus pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Systemic Lupus Erythematosus treatment.
• The leading Systemic Lupus Erythematosus Companies such as Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Resolve, Provention Bio, Pfizer, Novartis Pharmaceuticals, Novartis, Neovacs, Merck KGaA, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Therapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others.
• Promising Systemic Lupus Erythematosus Therapies such as Obexelimab, Telitacicept, DS-7011a, Belimumab (GSK1550188), Sirolimus, ALPN-101, and others.

Stay informed about the cutting-edge advancements in Systemic Lupus Erythematosus treatments. Download for updates and be a part of the revolution in care @ Systemic Lupus Erythematosus Clinical Trials Assessment- https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Systemic Lupus Erythematosus Emerging Drugs Profile
• Obinutuzumab (Gazyva): Roche
Gazyva/Gazyvaro is an engineered monoclonal antibody designed to attach to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells. Gazyva/Gazyvaro is designed to attack and destroy targeted B-cells both directly and together with the body's immune system.
Gazyva is marketed as Gazyvaro in the EU and Switzerland. Gazyva/Gazyvaro is currently approved in more than 90 countries in combination with chlorambucil for people with previously untreated chronic lymphocytic leukaemia, in more than 80 countries in combination with bendamustine for people with certain types of previously treated follicular lymphoma, and in more than 70 countries in combination with chemotherapy for previously untreated follicular lymphoma.
• Dapirolizumab pegol: UCB
Dapirolizumab pegol is an investigational humanized monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease. Dapirolizumab pegol is being co-developed with Biogen. The drug is currently in phase III stage of development to treat SLE.
• BIIB059: Biogen
BIIB059, discovered and developed exclusively by Biogen, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of SLE. BDCA2 is a receptor that is exclusively expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs), and it has been shown to reduce inflammatory cytokine production from pDCs, including type-I IFN (IFN-I). Inflammatory mediators are thought to play a major role in the pathogenesis of lupus. The drug has successfully completed Phase II and is currently in Phase III for SLE.
• PRV 3279: Provention Bio
PRV-3279 is an investigational humanized bispecific DART molecule targeting the B-cell surface proteins, CD32B and CD79B. Simultaneous engagement of the CD32B and CD79B receptors triggers inhibition of B cell function and suppression of autoantibody production, thereby regulating B cells without causing depletion. Provention is initially developing PRV-3279 for the interception of systemic lupus erythematosus (SLE), a chronic autoimmune disorder characterized by an abnormal over activation of B cells and subsequent pathologic production of auto-antibodies.
PRV-3279 also has the potential to prevent or reduce the immunogenicity of Biotherapeutics, including but not limited to gene therapy vectors and transgenes. Provention is currently evaluating PRV-3279 in the PREVAIL-2 (PRV-3279 Evaluation in Lupus) study.
• ABBV-599: AbbVie
ABBV-599 is a combination of ABBV-105 (BTK inhibitor) and ABT-494 (JAK1 Selective Inhibitor) under development for the treatment of Systemic Lupus Erythematosus (SLE). Upadacitinib (ABT-494) is an oral Janus kinase (JAK) 1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.
The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis.9 In December 2019, it was additionally approved by the European Commission. Upadacitinib is marketed under the brand name RINVOQ for oral administration. ABBV-105 irreversibly inhibits BTK, demonstrating superior kinome selectivity and is potent in B cell receptor, Fc receptor, and TLR-9-dependent cellular assays.

Learn more about Systemic Lupus Erythematosus Drugs opportunities in our groundbreaking Systemic Lupus Erythematosus Research and development projects @ Systemic Lupus Erythematosus Unmet Needs- https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Systemic Lupus Erythematosus Companies
Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Resolve, Provention Bio, Pfizer, Novartis Pharmaceuticals, Novartis, Neovacs, Merck KGaA, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Therapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others.

Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
· Intra-articular
· Intraocular
· Intrathecal
· Intravenous
· Ophthalmic
· Oral
· Parenteral
· Subcutaneous
· Topical
· Transdermal

Systemic Lupus Erythematosus Pipeline Products have been categorized under various Molecule types such as
· Oligonucleotide
· Peptide
· Small molecule

Discover the latest advancements in Systemic Lupus Erythematosus treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Systemic Lupus Erythematosus Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Systemic Lupus Erythematosus Pipeline Report
• Coverage- Global
• Systemic Lupus Erythematosus Companies- Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Resolve, Provention Bio, Pfizer, Novartis Pharmaceuticals, Novartis, Neovacs, Merck KGaA, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Therapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others.
• Systemic Lupus Erythematosus Therapies- Obexelimab, Telitacicept, DS-7011a, Belimumab (GSK1550188), Sirolimus, ALPN-101, and others.
• Systemic Lupus Erythematosus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Systemic Lupus Erythematosus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Systemic Lupus Erythematosus Pipeline on our website @ Systemic Lupus Erythematosus Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Systemic Lupus Erythematosus: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Systemic Lupus Erythematosus - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Obinutuzumab: Roche
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PRV 3279: Provention Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. E6742: Eisai
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Systemic Lupus Erythematosus - Collaborations Assessment- Licensing / Partnering / Funding
18. Systemic Lupus Erythematosus - Unmet Needs
19. Systemic Lupus Erythematosus - Market Drivers and Barriers
20. Appendix

List of Top Selling Market Research Reports in 2024

cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
orthopedic power devices market- https://www.delveinsight.com/report-store/orthopedic-power-devices-market
shingles market- https://www.delveinsight.com/report-store/shingles-market
short bowel syndrome market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-market
dyspepsia market- https://www.delveinsight.com/report-store/dyspepsia-market
liquid biospy for cancer diagnostics market- https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
perennial allergic rhinitis market- https://www.delveinsight.com/report-store/perennial-allergic-rhinitis-market
plaque psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
polycystic ovarian syndrome market- https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market
respiratory syncytial virus market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
sarcopenia market- https://www.delveinsight.com/report-store/sarcopenia-market
smoking cessation and nicotine addiction market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
catheter stabilization devices market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
nonalcoholic steatohepatitis market- https://www.delveinsight.com/blog/nonalcoholic-steatohepatitis-nash-highly-epidemic
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
pertussis market- https://www.delveinsight.com/report-store/pertussis-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
uk healthcare report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
viscosupplementation devices market- https://www.delveinsight.com/report-store/viscosupplementation-devices-market
bacterial meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cxcr inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
hdac inhibitors market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
plasmodium vivax malaria market- https://www.delveinsight.com/report-store/plasmodium-vivax-malaria-market
vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
venous ulcer market- https://www.delveinsight.com/report-store/venous-leg-ulcer-market
ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
pulmonary emphysema market- https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
somatotropin deficiency market- https://www.delveinsight.com/report-store/somatotropin-deficiency-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
tourette syndrome market- https://www.delveinsight.com/report-store/tourette-syndrome-market
external defibrillators market- https://www.delveinsight.com/report-store/defibrillator-market
plantar fasciitis market- https://www.delveinsight.com/report-store/plantar-fasciitis-market
scoliosis market- https://www.delveinsight.com/report-store/scoliosis-market
tendonitis market- https://www.delveinsight.com/report-store/tendonitis-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
peripheral nerve injuries market- https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
sepsis market- https://www.delveinsight.com/report-store/sepsis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
healthcare consulting solutions- https://www.delveinsight.com/consulting
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
TCR therapy market- https://www.delveinsight.com/report-store/t-cell-receptor-tcr-therapy-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
Nontuberculous Mycobacterial Market- https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
intraocular lens market https://www.delveinsight.com/report-store/intraocular-lens-market
orthopedic splints device market- https://www.delveinsight.com/report-store/orthotic-devices-market
transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
skin neoplasm market- https://www.delveinsight.com/blog/skin-cancer-treatment-market-and-key-companies
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.